We analyzed the effects of T-cell depletion on the outcome of HLA-identical sibling bone marrow transplants for leukemia by comparing 731 T-cell-depleted transplants with 2,480 non-T-cell-depleted transplants. T-cell depletion decreased acute graft-versus-host disease (GVHD) (relative risk [RR] 0.45; P < .Mol) and chronic GVHD (RR 0.56; P < .Mol). However, it increased graft failure (RR 9.29; P < .OOOl).
The publication costs of this article were defrayed in part by page charge payment. 7% article must therefore be hereby marked "advertisement" in accordance with I8 U.S. C human models, that both acute and chronic GVHD decrease leukemia relapse and contribute importantly to the antileukemia efficacy of allogeneic transplant^."^ Despite this beneficial effect, GVHD is an important problem after transplant and removing T cells from donor BM was proposed as a logical procedure to prevent GVHD in human^.'^ There are several published studies of T-celldepleted BMTs"-*~ as well as several recent re~iews.2~"~ These data suggest that T-cell depletion decreases acute and probably chronic GVHD. However, these data also suggest that T-cell depletion increases graft failure and leukemia relapse. There is a debate over whether T-cell depletion affects leukemia-free survival (LFS). A major problem in evaluating reports of T-cell-depleted transplants is that most studies contain few subjects with different leukemias in various remission states and do not address differential effects of T-cell depletion in different leukemias. It is also difficult, with small numbers of subjects, to adjust for effects of other factors affecting transplant outcome like age and leukocytes at d i a g n~s i s .~.~~,~' In addition, most studies focus on a single method of T-cell depletion. Under these circumstances, it is not possible to compare different techniques of T-cell depletion. Studies that do include more than one method of T-cell depletion generally do not compare outcome with different methods.
In this study, we asked two questions: (1) how do the results of T-cell-depleted transplants between HLAidentical siblings compare with those of non-T-celldepleted transplants? and (2) what factors predict the outcome of T-cell-depleted transplants? To answer these questions, we analyzed data from 3,211 patients with leukemia: 731 recipients of T-cell-depleted transplants and 2,480 recipients of non-T-cell-depleted transplants. We used statistical techniques to adjust for the effect of other patient-, disease-, and treatment-related factors and compared different methods of T-cell depletion.
MATERIALS AND METHODS

Study Cohort
The study cohort includes all patients receiving T-cell-depleted HLA-identical sibling BMTs for acute lymphoblastic leukemia (ALL), acute myelogenous leukemia (AML), and chronic myeloge- Table 1 .
Disease state at the time of transplant was defined as early (first remission for acute leukemia and first chronic phase for CML), intermediate (second or subsequent remission for acute leukemia and accelerated phase for CML), and advanced (partial remission or relapse for acute leukemia and acute phase for CML). Graft failure was analyzed in patients surviving 2 21 days posttransplant using published criteria.36 Grade 2 to 4 acute GVHD was defined using published criteria'; patients surviving 2 2 1 days with evidence of engraftment were considered at risk. Chronic GVHD was determined by clinical criteria in subjects surviving 2 90 days with evidence of engraftment." Remission of acute leukemia was defined as absence of leukemia in any site. Relapse and remission of CML were defined using published criteria.u Only persons with hematologic evidence of CML were scored as relapse.
T-cell Depletion Methods
A variety of T-cell depletion techniques are used by centers participating in the IBMTR. These techniques were grouped into four categories for analysis: (1) physical techniques (lectin separation, elutriation, E-rosettes); (2) antibodies reactive against T cells only; (3) antibodies reactive against T and natural killer (NK) cells; and (4) Campath-I, which has bread specificity against hematopoietic cells. Assignment of individual techniques to one of these groups was done independently by three individuals (R.C.A.; Richard J. O'Reilly, Memorial Sloan-Kettering Cancer Center, New York, NY; and George Janossy, Royal Free Hospital, London, UK) blinded to other clinical data and transplant centers. Only techniques for which there was unanimous agreement regarding specificity were included in analyses comparing T-cell depletion methods.
1
Statistical Methods
The distribution of potentially important prognostic variables, as identified in prior IBMTR and other studies, were compared between the study and control groups using the x2 statistic for categorical and the Mann-Whitney test for continuous variables ( Table 1) . Actuarial probabilities of graft failure, grade 2 to 4 acute GVHD, chronic GVHD, relapse, and LFS were calculated using the life-table Survival curves were terminated when fewer than five patients remained at risk.
Relative risks of graft failure, grade 2 to 4 acute GVHD, chronic GVHD, clinical relapse, and treatment failure (relapse or death from any cause) after T-cell-depleted versus non-T-cell-depleted transplants were calculated using Cox proportional hazards regression to adjust for potentially confounding differences in other patient-, disease-, and donor-related variables.@ Variables differing significantly between T-cell-depleted and non-T-celldepleted graft recipients ( Table 1) were included as covariates in these regression equations. Non-T-cell-depleted controls included patients transplanted at centers performing no T-cell-depleted transplants and those transplanted at centers performing both T-cell-depleted and non-T-cell-depleted transplants. We compared the outcomes of non-T-cell-depleted transplants at these two types of centers, to determine whether differences might have confounded results. After adjustment for patient-and diseaserelated prognostic variables, all outcomes were similar whether patients received their non-T-cell-depleted transplants at a center that did or did not also perform T-cell-depleted transplants. The association of T-cell depletion with the outcome variable calculated from the multivariate models represents its association independent of any association with other covariates. Regression models including acute and chronic GVHD as time-dependent covariates were used to determine whether relapse risk differed between T-cell-depleted and non-T-cell-depleted cohorts, independent of differences in the incidence of GVHD.4'
To identify factors correlated with outcome of T-cell-depleted transplants, recipients of T-cell-depleted transplants were analyzed separately. Variables in Table l were examined for associations with graft failure, grade 2 to 4 acute GVHD, chronic GVHD, relapse, and treatment failure in univariate analysis using the Lee-Desu statistic." Variables associated with transplant outcome in univariate analysis with P < .1 were evaluated in multivariate analysis using Cox proportional hazards regression and a forward stepwise approach.40 Variables improving the model at the P < .05 level were included in the final model. Since 1987, IBMTR questionnaires requested data regarding T-cell dose. Information on total number of T cells transplanted was available for 263 of 731 T-cell-depleted transplants. Different techniques were used by different centers to quantify numbers of T cells infused. These can be categorized into those with a lower limit of sensitivity of about 1% (such as E-rosette formation or fluorescence-activated cell sorter [FACS] analyses using fluorescentlabeled murine monoclonal antibody [MoAb] to T cells) and those with a lower limit of sensitivity of about 0.1% to 0.01% T cells (such as limiting dilution analysis). The effect of T-cell dose was similar regardless of method of quantitation used, and only results of pooled data are reported. T-cell dose was excluded from consideration in the initial multivariate analyses, because information was available for only about one-third of the patients. The effect of T-cell dose on outcome was subsequently examined in evaluable patients after adjusting for other variables significantly associated with outcome.
Results of multivariate analyses were examined for possible influence by differences among centers (1) by entering center size (the average number of transplants done annually) as a covariate; (2) by stratifying on center size; (3) by repeating each analysis after excluding a 5% random sample of teams (this was done a minimum of three times for each regression equation); and (4) by repeating each analysis after excluding patients from each of the eight largest teams, in turn. No substantial difference in the relative risks associated with T-cell depletion or other prognostic variables was detected with any of these procedures. Factors predictive of outcome were valid at both small and large centers.
All P values are two-sided and based on multivariate analyses unless otherwise specified. Because of the large number of comparisons made, we considered only P values <.01 as statistically significant. P values between .01 and .05 are presented to show trends but should be interpreted with caution.
RESULTS
Comparison of T-Cell-Depleted and Non-T-Cell-Depleted Transplants
T-cell depletion was associated with significantly increased risk of graft failure (relative risk [RR] 9.29; P < .Owl) (Fig 1) . This effect was observed in ALL, AML, and CML and early, intermediate, and advanced leukemia.
Recipients of T-cell-depleted grafts had reduced risk of use only. (8) 371 (65) 43 (26) 18 (11) 106 (64) 128 (15) 289 (35) 105 (13) 211 (26) 93 (11) 44 (20) 83 (37) 32 (14) 42 ( grade 2 to 4 acute GVHD (RR 0.45; P < .0001) and chronic GVHD (RR 0.56; P < .OOOl) (Fig 1) . This effect was also detected in ALL, AML, and CML and in all remission states. The incidence of interstitial pneumonia was similar after T-cell-depleted and non-T-cell-depleted transplants (RR 0.97; P = NS).
We compared the likelihood of leukemia relapse between T-cell-depleted and non-T-cell-depleted transplants after stratifying for type of leukemia and disease state ( Table 2, Fig 2) . These data indicate significantly increased leukemia relapse for all T-cell-depleted groups except AML in 2 2nd remission and CML in blast phase. The adverse effect on relapse in early leukemia was greatest in CML (RR 5.61; P < .0001), intermediate in AML (RR 1.94; P < .007), and least in ALL (RR 1.83; P < .05).
Because T-cell depletion decreases GVHD, and because GVHD is correlated with relap~e,~-''~'~ analyses were repeated after adjusting for incidence and severity of acute and chronic GVHD. After adjusting for GVHD, the relative relapse risks for AML and ALL in first remission and CML in chronic phase were 1.66 (P = NS), 1.55 (P = NS), and 4.87 (P < .Owl), respectively.
T-cell depletion was also associated with increased treatment failure (relapse or death from any cause) in early (RR 1.35; P < .0005) and advanced leukemia (RR 1.60; P < .002); the effect in intermediate leukemia was not significant (RR 1.21) (Table 3, Fig 3) . In early leukemia, the increase was largest for AML (RR 1.41, P < .02); in advanced leukemia the increase was larger in ALL (RR 1.66, P < .02) and CML (RR 1.83, P < .02). In no disease or leukemia state did T-cell depletion significantly decrease the risk of treatment failure.
Factors Determining Outcome of T-Cell-Depleted Transplants
We next investigated potentially controllable factors associated with outcome of T-cell-depleted transplants.
Gruff failure. Factors correlated with graft failure are shown in Table 4 . Controllable factors included radiation dose (RR 0.40 for doses > 12 Gy v I 12 Gy; P < .007); dose rate (RR 0.40 for dose rates < 14 v 2 14 cGy/min; P < .002);
and posttransplant immune suppression with methotrexate and/or cyclosporine (RR 0.32; P < .0003). Although dose and dose rate are confounded variables, there is no generally accepted technique to adjust for these in the setting of acute high-dose total body radiation. Both were significant in multivariate analyses, with increases in each associated with lower risk of graft failure. Two additional factors were correlated with graft failure: recipient age (RR 2.79 for ages 2 2 0 v <20 years; P < .0007) and sex-mismatched transplants (RR 2.02; P < .004). The risk of graft failure 
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Months was somewhat higher with male donor to female recipient transplants (RR 2.45) than the reverse (RR 1.67); this difference was not statistically significant. Factors correlated with GVHD are shown in Table 5 . Posttransplant methotrexate plus cyclosporine reduced the likelihood of acute GVHD (RR 0.22; P < .02) after T-cell-depleted transplants. This effect was not detected with methotrexate or cyclosporine alone. Pretransplant performance score also predicted acute GVHD; Karnofsky scores less than 100% were associated with increased risk (RR 1.50; P < .03). The risk of chronic GVHD increased when donors and recipients were of different sex (RR 1.83; P < .0006); male-to-female and female-to-male transplants had comparable risks. Higher radiation dose rates also tended to be associated with higher risk of chronic GVHD (RR 1.51 for dose rates > 14 v -< 14 cGy/min; P < .03).
Factors correlated with relapse in early leukemia are shown in Table 6 . These factors include radiation dose (RR 0.45 for doses 211 Gy v <11 Gy; P < .03) and fractionation (RR 3.95; P < .00;3). The latter was usually administered in five to seven fractions of 2
GVHD.
Leukemia relapse. to 2.5 Gy. Radiation dose and fractionation are confounded variables. However, there is no generally accepted technique to adjust these variables to define a relative biologic effect in the context of acute high-dose total body radiation. This situation is further confounded by effects of different dose rates of radiation. All regression equations examining the effect of radiation on outcome included terms for total dose, dose rate, and fractionation. To simplify this, we performed further analyses of two well-defined subsets, comparing 28 patients receiving 10 Gy of single dose total body radiation at dose rates less than 10 cGy/min with 46 patients receiving 12 Gy total body irradiation in six fractions at similar dose rates. Here again, fractionation resulted in an increased relapse risk (RR 1.91). The method of T-cell depletion also was associated with relapse risk. different physical techniques such as elutriation, lectin separation, or E-rosette depletion. Factors correlated with treatment failure are shown in Table 7 . These factors included posttransplant immune suppression with cyclosporine with (RR 0.35; P < .008) or without (RR 0.51; P < .0004) methotrexate, and use of anti-T antibodies for T-cell depletion (RR 2.13; P < .02). Radiation-related variables such as dose (RR 0.52 for doses 211 Gy v < l l Gy; P < .006), dose rate (RR 0.55 for dose rates 2 12 v < 12 cGy/min; P < .002), and fractionation (RR 1.70; P < .04) also influenced the risk of treatment failure as did age (RR 1.65 for ages 2 20 years v < 20 years; P < .0007).
The effect of T-cell dose on transplant outcome was evaluated in the subset of 263
Treatment failure.
Effect of T-cell dose. patients for whom this information was available. Doses greater than 106/kg recipient weight were associated with increased acute GVHD (RR 3.8, P < .005) and less relapse (RR 0.1, P < .01). T-cell dose was not significantly associated with graft failure, chronic GVHD, or LFS.
Variables not correlated with transplant outcome. Important variables not significantly correlated with the outcome of T-cell-depleted transplants in multivariate analyses included total numbers or dose of nucleated BM cells, addition of other drugs to cyclophosphamide, and total body radiation in the pretransplant preparative regimen use of total lymphoid radiation, transplant center, and year of transplant. 
DISCUSSION
This study addressed two issues: (1) the outcome of HLA-identical T-cell-depleted versus non-T-cell-depleted transplants for leukemia, and (2) controllable variables influencing outcome of T-cell-depleted transplants.
The comparison of the outcome of T-cell-depleted and non-T-cell-depleted transplants is complex. First, it is necessary to examine and adjust treatment groups for differences in risk factors for GVHD, such as age, sexmatching, and donor parity. Second, results may depend on the type of leukemia and on leukemia state. Next, it is necessary to adjust for other variables affecting transplant outcome, such as age, leukocytes at diagnosis, and, possibly, French-American-British (FAB) type in patients with AML and ALL in first remis~ion.~.'~ Finally, it is appropriate to consider other treatment factors that might influence outcome of T-cell-depleted and/or non-T-cell-depleted transplants, such as the pretransplant conditioning regimen and type of posttransplant immune s~p p r e s s i o n .~~
The large numbers of subjects needed for this type of multivariate analysis were achieved in this study by pooling data for 3,211 transplant recipients. Analysis of smaller series is unlikely to answer these questions because the group sizes achieved even with this large database were sometimes too small for sufficient statistical power.
Using the approach outlined, we show that T-cell depletion, as used by the transplant teams reporting to the IBMTR, did not increase LFS; in several situations, LFS was decreased. The reason for this is that, although T-cell depletion decreased acute and chronic GVHD, graft failure and leukemia relapse were increased. Similar findings are reported in other smaller series and in reviews previously cited. However, few of these reports had sufficient subjects to analyze different types of leukemia and remission states or to correct for other variables predicting GVHD or leukemia relapse. This lack of subjects may explain why several studies failed to detect the findings reported here.
The increased relapse after T-cell-depleted transplants for ALL and AML appears to be wholly explained by the decreased incidence of GVHD and, presumably, GVHDassociated antileukemia effects. Relapse risk was significantly increased after T-cell-depleted versus non-T-celldepleted transplants for CML, even after adjusting for differences in GVHD incidence. These data suggest that other mechanisms may operate in CML."
Because of the large number of subjects receiving T-celldepleted transplants under diverse circumstances, it was possible to analyze variables predicting outcome of these transplants and to address several controversial points. For example, some previously cited smaller studies and reviews suggest that posttransplant immune suppression increases relapse after T-cell-depleted transplants. This was not found in this study. Furthermore, perhaps because it decreased GVHD and rejection, posttransplant immune suppression was associated with increased LFS.
It is suggested that variable risks of leukemia relapse between small series may reflect different techniques of T-cell depletion. Some techniques may remove only T cells, whereas others remove additional cell types, like NK cells, or affect numbers of hematopoietic stem cells transplanted. The data presented indicate complexities in this analysis. For example, the three antibody techniques were associated with increased risks of relapse (this was only of borderline significance for anti-T antibodies) compared with physical techniques. Why this should be so is unclear because physical techniques would appear to be as nonspecific in removing cells as broad specificity antibodies.
T cells are clearly important in causing GVHD. In murine models T-cell dose is correlated with incidence and severity of acute GVHD.14 This correlation is likely true in humans because T-cell depletion decreases acute GVHD. We detected a modest effect of T-cell dose in this analysis with doses greater than 106/kg recipient weight associated with increased GVHD and decreased relapse. However, T-cell dose did not affect LFS.
It appears that some of the problems engendered by T-cell depletion can be reduced by higher doses and dose rates of radiation, and by avoiding fractionation. In contrast to several smaller studies, we found no evidence that adding other drugs or total lymphoid radiation to cyclophosphamide and total body radiation reduced graft failure or leukemia relapse. Also, there was no independent correlation between the dose of T cells or BM cells and the likelihood of graft failure. Nor was any specific technique of T-cell depletion associated with less graft rejection. These data suggest that the quality or efficacy of T-cell depletion, within the range achieved by methods used during the period of study, is not responsible for different graft failure rates.
The data set we studied was heterogenous. Different centers used different techniques of T-cell depletion and different assays of residual T cells. Although some may argue against combining such data, there are several advantages to this approach. First, as discussed, it is not possible to critically evaluate results of T-cell depletion without pooling data. Second, although different techniques of T-cell depletion and assaying residual T cells were used, neither of these factors influenced the likelihood of decreasing GVHD, suggesting that all were comparably effective. Third, except for leukemia relapse, we found no evidence that any technique produced different results. Even here, results with the three types of antibodies were similar. Furthermore, there is no perfect or widely agreed on technique for evaluating residual T cells; each approach has its proponents and the relationship between T-cell dose and outcome was not affected by the method used for quantification. Finally, the effect of pooling diverse data is to make prognostic factors more rather than less difficult to detect because of increased background heter~geneity.~~ Consequently, we are likely to underestimate the impact of the variables identified. It is possible that some variables of prognostic import were obscured by pooling data. However, the additional statistical power associated with the large number of subjects in this study partially offsets this problem.
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For personal at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From In summary, the data presented indicate that T-cell depletion decreases GVHD but increases graft failure and leukemia relapse; LFS is not improved and is even decreased in some settings. These conclusions only apply to approaches used before 1988. Whether more recent approaches such as depletion of selected T-cell subsets or adding back radiated T cellsz will alter outcome of T-celldepleted transplants is not yet known.
Several controllable variables are associated with transplant outcome. For example, higher doses and dose rates and fewer fractions of total body radiation are associated with a better overall outcome of T-cell-depleted transplants. The same is true of physical techniques of T-cell depletion and posttransplant immune suppression with cyclosporine. Selecting subjects at greatest risk for GVHD combined with optimizing these controllable variables might improve outcome of T-cell-depleted transplants. 
